|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pantuck AJ, Zisman A and Belldegrun AS:
The changing natural history of renal cell carcinoma. J Urol.
166:1611–1623. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garzon R and Marcucci G: Potential of
microRNAs for cancer diagnostics, prognostication and therapy. Curr
Opin Oncol. 24:655–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kurozumi A, Goto Y, Okato A, Ichikawa T
and Seki N: Aberrantly expressed microRNAs in bladder cancer and
renal cell carcinoma. J Hum Genet. 62:49–56. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gu L, Li H, Chen L, Ma X, Gao Y, Li X,
Zhang Y, Fan Y and Zhang X: MicroRNAs as prognostic molecular
signatures in renal cell carcinoma: A systematic review and
meta-analysis. Oncotarget. 6:32545–32560. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang XH, Chen JS, Wang Q, Chen XL, Wen L,
Chen LZ, Bi J, Zhang LJ, Su Q and Zeng WT: miR-338-3p suppresses
invasion of liver cancer cell by targeting smoothened. J Pathol.
225:463–472. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fu X, Tan D, Hou Z, Hu Z, Liu G, Ouyang Y
and Liu F: The effect of miR-338-3p on HBx deletion-mutant
(HBx-d382) mediated liver-cell proliferation through CyclinD1
regulation. PloS One. 7:e432042012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun K, Deng HJ, Lei ST, Dong JQ and Li GX:
miRNA-338-3p suppresses cell growth of human colorectal carcinoma
by targeting smoothened. World J Gastroenterol. 19:2197–2207. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wen C, Liu X, Ma H, Zhang W and Li H:
miR3383p suppresses tumor growth of ovarian epithelial carcinoma by
targeting Runx2. Int J Oncol. 46:2277–2285. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li P, Chen X, Su L, Li C, Zhi Q, Yu B,
Sheng H, Wang J, Feng R, Cai Q, et al: Epigenetic silencing of
miR-338-3p contributes to tumorigenicity in gastric cancer by
targeting SSX2IP. PloS One. 8:e667822013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo B, Liu L, Yao J, Ma R, Chang D, Li Z,
Song T and Huang C: miR-338-3p suppresses gastric cancer
progression through a PTEN-AKT axis by targeting P-REX2a. Mol
Cancer Res. 12:313–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jin Y, Zhao M, Xie Q, Zhang H, Wang Q and
Ma Q: MicroRNA-338-3p functions as tumor suppressor in breast
cancer by targeting SOX4. Int J Oncol. 47:1594–1602. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen X, Ruan A, Wang X, Han W, Wang R, Lou
N, Ruan H, Qiu B, Yang H and Zhang X: miR-129-3p, as a diagnostic
and prognostic biomarker for renal cell carcinoma, attenuates cell
migration and invasion via downregulating multiple
metastasis-related genes. J Cancer Res Clin Oncol. 140:1295–1304.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang G and Sun Y, He Y, Ji C, Hu B and Sun
Y: MicroRNA-338-3p inhibits cell proliferation in hepatocellular
carcinoma by target forkhead box P4 (FOXP4). Int J Clin Exp Pathol.
8:337–344. 2015.PubMed/NCBI
|
|
21
|
Huang N, Wu Z, Lin L, Zhou M, Wang L, Ma
H, Xia J, Bin J, Liao Y and Liao W: miR-338-3p inhibits
epithelial-mesenchymal transition in gastric cancer cells by
targeting ZEB2 and MACC1/Met/Akt signaling. Oncotarget.
6:15222–15234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Han R, Huang S, Bao Y, Liu X, Peng X, Chen
Z, Wang Q, Wang J, Zhang Q, Wang T, et al: Upregulation of SOX4
antagonizes cellular senescence in esophageal squamous cell
carcinoma. Oncol Lett. 12:1367–1372. 2016.PubMed/NCBI
|
|
23
|
Wang L, Zhang J, Yang X, Chang YW, Qi M,
Zhou Z, Zhang J and Han B: SOX4 is associated with poor prognosis
in prostate cancer and promotes epithelial-mesenchymal transition
in vitro. Prostate Cancer Prostatic Dis. 16:301–307. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin CM, Fang CL, Hseu YC, Chen CL, Wang
JW, Hsu SL, Tu MD, Hung ST, Tai C, Uen YH and Lin KY: Clinical and
prognostic implications of transcription factor SOX4 in patients
with colon cancer. PloS One. 8:e671282013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Song GD, Sun Y, Shen H and Li W: SOX4
overexpression is a novel biomarker of malignant status and poor
prognosis in breast cancer patients. Tumour Biol. 36:4167–4173.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hur W, Rhim H, Jung CK, Kim JD, Bae SH,
Jang JW, Yang JM, Oh ST, Kim DG, Wang HJ, et al: SOX4
overexpression regulates the p53-mediated apoptosis in
hepatocellular carcinoma: Clinical implication and functional
analysis in vitro. Carcinogenesis. 31:1298–1307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang D, Hao T, Pan Y, Qian X and Zhou D:
Increased expression of SOX4 is a biomarker for malignant status
and poor prognosis in patients with non-small cell lung cancer. Mol
Cell Biochem. 402:75–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu CC, Chen PN, Peng CY, Yu CH and Chou
MY: Suppression of miR-204 enables oral squamous cell carcinomas to
promote cancer stemness, EMT traits and lymph node metastasis.
Oncotarget. 7:20180–20192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shi S, Cao X, Gu M, You B, Shan Y and You
Y: Upregulated expression of SOX4 is associated with tumor growth
and metastasis in nasopharyngeal carcinoma. Dis Markers.
2015:6581412015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Parvani JG and Schiemann WP: Sox4, EMT
programs, and the metastatic progression of breast cancers:
Mastering the masters of EMT. Breast Cancer Res. 15:R722013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Y, Chen P, Zu L, Liu B, Wang M and Zhou
Q: MicroRNA-338-3p suppresses metastasis of lung cancer cells by
targeting the EMT regulator Sox4. Am J Cancer Res. 6:127–140.
2016.PubMed/NCBI
|
